Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac

Thangirala Sudha, Dhruba J. Bharali, Murat Yalcin, Noureldien H.E. Darwish, Melis Debreli Coskun, Kelly A. Keating, Hung Yun Lin, Paul J. Davis, Shaker A. Mousa

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)


Aim: Nano-diamino-tetrac (NDAT) targets a receptor on integrin αvβ3; αvβ3 is generously expressed by cancer cells and dividing endothelial cells and to a small extent by nonmalignant cells. The tetrac (tetraiodothyroacetic acid) of NDAT is covalently bound to a poly(lactic-co-glycolic acid) nanoparticle that encapsulates anticancer drugs. We report NDAT delivery efficiency of cisplatin to agent-susceptible urinary bladder cancer xenografts. Materials & methods: Cisplatin-loaded NDAT (NDAT-cisplatin) was administered to xenograft-bearing nude mice. Tumor size response and drug content were measured. Results: Intratumoral drug concentration was up to fivefold higher (p < 0.001) in NDAT-cisplatin-exposed lesions than with conventional systemic administration. Tumor volume reduction achieved was NDAT-cisplatin > NDAT without cisplatin > cisplatin alone. Conclusion: NDAT markedly enhances cisplatin delivery to urinary bladder cancer xenografts and increases drug efficacy.

Original languageEnglish
Pages (from-to)195-205
Number of pages11
Issue number3
Publication statusPublished - Feb 2017


  • NDAT
  • cisplatin
  • integrin
  • nanotetrac
  • tetraiodothyroacetic acid
  • urinary bladder carcinoma

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Materials Science(all)


Dive into the research topics of 'Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac'. Together they form a unique fingerprint.

Cite this